Results 241 to 250 of about 14,937 (281)

Educational inequalities in cervical cancer mortality in the Baltic countries and Finland in the context of organized screening: A register‐based study 2000–2015

International Journal of Cancer, EarlyView.
What's New? This study shows that absolute and relative educational inequalities in cervical cancer mortality are much larger in the Baltic countries than in Finland, where an organized screening programme was introduced more than 40 years earlier. After the introduction of organized screening, cervical cancer mortality declined among low‐educated ...
Oskar Nõmm, Kaire Innos, Domantas Jasilionis, Juris Krumins, Pekka Martikainen, Kersti Pärna, Andrew Stickley, Mall Leinsalu   +7 more
wiley   +1 more source

Th17 cells favor migration and invasiveness of cervical cancer cells under hypoxia in an IGF2BP2‐dependent manner

International Journal of Cancer, EarlyView.
What's New? Hypoxic regions and inflammatory Th17 cells in the tumor environment are both associated with poor prognosis in cervical cancer. However, synergistic mechanisms between hypoxia and Th17 cells remain elusive. This study demonstrated Th17–hypoxia‐driven mechanisms underlying cervical cancer progression.
Selina Gies, Maike Pohlers, Tanja Tänzer, Emmanuel Ampofo, Matthias W. Laschke, Moritz Schäfer, Yoo‐Jin Kim, Rainer Maria Bohle, Erich‐Franz Solomayer, Konrad Wagner, Martin Empting, Alexandra K. Kiemer, Barbara Walch‐Rückheim   +12 more
wiley   +1 more source

The obstetrician attached to the obstetric emergency. [PDF]

Colomb Med (Cali)
Villalobos Rodríguez AL.
europepmc   +1 more source

Cost‐effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV‐positive women in cervical cancer screening

International Journal of Cancer, EarlyView.
What's New? Persistent infection with high‐risk human papillomavirus (HPV) causes most invasive cervical cancer cases, leading many countries to transition from cytology to primary HPV‐based screening. Despite the benefits, HPV‐based screening may also lead to unnecessary procedures, psychological burden, and strain on healthcare systems.
Kelsi R. Kroon, Johannes A. Bogaards, Johannes Berkhof   +2 more
wiley   +1 more source

Health care policy trial of primary human papillomavirus–based cervical screening in Denmark: Comparison of three triage algorithms

International Journal of Cancer, EarlyView.
What's New? Primary human papillomavirus (HPV)–based screening has shown superiority to cytology‐based screening in reducing cervical cancer risk in clinical trials. However, the benefit must be balanced with potential overdiagnosis/overtreatment.
Jeppe Bennekou Schroll, Jesper Bonde, Elsebeth Lynge, Marianne Waldstrøm, Petra Hall Viborg, Anna Frandsen, Rikke Holst Andersen, Susanne Merete Nielsen, Bettina Kjær Kristensen, Doris Schledermann, Berit Andersen, on behalf ofthe National Danish Cervical Cancer Screening Steering Committee   +11 more
wiley   +1 more source

Clinical and genetic description of patients with chronic granulomatous disease in a pediatric hospital [PDF]

Biomedica
Berriozábal-Villarruel X, Godínez-Zamora GF, Baeza-Capetillo P, Pérez-Blanco U, Espinosa-Padilla SE, Aguirre-Hernández J, Blancas-Galicia L, Saucedo-Ramírez OJ.   +7 more
europepmc   +1 more source

Correlación Citológica, Colposcopía, e Histopatología de Lesiones Escamosas Intraepiteliales de alto grado de Cérvix en la clínica de Colposcopía del Hospital General de Ecatepec Dr José María Rodríguez. Marzo 2010 a febrero 2013 [PDF]

, 2014
Avellaneda Atriano, Citlalli Eunice, Carrillo Pacheco, Adia   +1 more
core  

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions (VIVA trial): A randomized, double‐blind, placebo‐controlled trial

International Journal of Cancer, EarlyView.
What's New? Anal and vulvar high‐grade squamous intraepithelial lesions (HSILs) frequently recur following treatment. Additional genital and anal procedures, however, can be distressing for patients and are potentially disfiguring. This trial assessed whether the 9‐valent human papillomavirus (9vHPV) vaccine reduces HSIL recurrence risk or HPV ...
Helen C. Stankiewicz Karita, Amalia S. Magaret, David R. Doody, Jeffrey T. Schouten, Constance Mao, Warner K. Huh, Verena S. Grieco, Matthew A. Seymour, Dana Varon, Kelly H. Shrader, Long Fu Xi, Denise A. Galloway, Anna Wald, Margaret M. Madeleine   +13 more
wiley   +1 more source